Pancreatic Neuroendocrine TumorNCT02624154
Pancreatic Neuroendocrine Tumor：Factor of Surgery Influencing Survival
An observational study of Pancreatic Neuroendocrine Tumor, run by First Affiliated Hospital, Sun Yat-Sen University.
Trial summary
Investigator determined the factor of surgery associated with the survival of pancreatic neuroendocrine tumor. Read more about this study
- Who is it for?
- Ages 10 to 80 years
- Conditions the study is for
- Pancreatic Neuroendocrine Tumor
- What is being tested?
- pancreatectomy
- Type of treatment
- Surgery or procedure
- How many people
- 2 participants
- Where
- No sites listed yet
- Study dates
- Dec 2015to Dec 2016
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 10 to 80 years
- All sexes
- No healthy volunteers
- Child, Adult, Older adult
Study population: Investigators selected the patient who underwent pancreatectomy during the time from 2010 to 2013 at the First Affiliated Hospital of Sun Yat-sen University.
Who may be able to join
- The patients with pancreatic neuroendocrine tumor underwent pancreatectomy
Who cannot join
- The patients with pancreatic neuroendocrine tumor did not undergo pancreatectomy
Trial locations and contacts
No sites are listed yet.
About this study
Investigator determined the factor of surgery associated with the survival of pancreatic neuroendocrine tumor.
Read the detailed description
The variables including clinical characteristics, surgical data and pathological findings are examined by univariate and multivariate analyses.
- Conditions
- Pancreatic Neuroendocrine Tumor
- Being tested
- pancreatectomy
- Medical subject headings
- Adenoma, Islet Cell
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
pancreatectomyProcedure or surgery
Remove the pancreatic neuroendocrine tumor by surgery
What is being measured
The primary outcome is the main question the study is designed to answer.
The survival rate
Measured: 3 years
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted8 Dec 2015 (estimated)
- Study startDec 2015
- Primary completionJun 2016 (estimated)
- Study completionDec 2016 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Pancreatic Neuroendocrine TumorStudies of the same condition, open and under way.
- More trials run by First Affiliated Hospital, Sun Yat-Sen UniversityThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Case only
- Time perspective
- Retrospective
- Enrolment
- 2 participants (estimated)
Sponsor and investigators
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Qinchang Chen, First Affiliated Hospital, Sun Yat-Sen University
- Investigators
- Shaowei Gao, Doctor, Study director, First Affiliated Hospital, Sun Yat-Sen University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT02624154
- Sponsor's protocol ID
- SYSU 211
- Status last verified
- Nov 2015
- First submitted
- 30 Nov 2015
- Last updated
- 8 Dec 2015
- Results posted
- No
- Data monitoring committee
- Yes
Study at a glance
From the registry record, last updated by the sponsor on 8 Dec 2015. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Pancreatic Neuroendocrine Tumor：Factor of Surgery Influencing Survival
- ClinicalTrials.gov ID
- NCT02624154
- Acronym / sponsor ID
- SYSU 211
- Conditions
- Pancreatic Neuroendocrine Tumor
- Study type
- Observational
- Recruitment status
- Unknown status
- Enrolment
- 2 participants (estimated)
- Lead sponsor
- First Affiliated Hospital, Sun Yat-Sen UniversityUniversity, hospital or other
- Study start
- Dec 2015
- Primary completion
- Jun 2016 (estimated)
- Study completion
- Dec 2016 (estimated)
- First posted
- 8 Dec 2015 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Investigator determined the factor of surgery associated with the survival of pancreatic neuroendocrine tumor.
Detailed description
The variables including clinical characteristics, surgical data and pathological findings are examined by univariate and multivariate analyses.
Study design
- Observational model
- Case only
- Time perspective
- Retrospective
Who may qualify
- Ages
- 10 to 80 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Child, Adult, Older adult
- Study population
- Investigators selected the patient who underwent pancreatectomy during the time from 2010 to 2013 at the First Affiliated Hospital of Sun Yat-sen University.
Key inclusion criteria (1 listed)
- The patients with pancreatic neuroendocrine tumor underwent pancreatectomy
Key exclusion criteria (1 listed)
- The patients with pancreatic neuroendocrine tumor did not undergo pancreatectomy
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| pancreatectomyRemove the pancreatic neuroendocrine tumor by surgery | Procedure or surgery | – |
Primary outcome
The survival rate
Time frame: 3 years
Results and safety
Results are not available in the source record.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 8 Dec 2015.
Related trials for Pancreatic Neuroendocrine Tumor
RecruitingPhase 2
At-Home Cancer Directed Therapy Versus in Clinic for the Treatment of Patients With Advanced Cancer
Advanced Anal Carcinoma, Advanced Biliary Tract Carcinoma
RecruitingPhase 2
Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Cancer
Metastatic Colorectal Cancer, Metastatic Pancreatic Cancer
RecruitingObservational study
Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia
RecruitingPhase 2
A Study of Navlimetostat (BMS-986504) Monotherapy and in Combination With Other Agents in Participants With Advanced and/or Metastatic Solid Tumors With Homozygous MTAP Deletion (MountainTAP-5)
Solid Tumors
RecruitingPhase 2
Belzutifan/MK-6482 for the Treatment of Advanced Pheochromocytoma/Paraganglioma (PPGL), Pancreatic Neuroendocrine Tumor (pNET), Von Hippel-Lindau (VHL) Disease-Associated Tumors, Advanced Gastrointestinal Stromal Tumor (wt GIST), or Solid Tumors With HIF-2α Related Genetic Alterations (MK-6482-015)
Pheochromocytoma/Paraganglioma, Pancreatic Neuroendocrine Tumor
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Shaowei Gao, Doctor study director
First Affiliated Hospital, Sun Yat-Sen University
Questions about this trial
What is this clinical trial studying?
An observational study of Pancreatic Neuroendocrine Tumor, run by First Affiliated Hospital, Sun Yat-Sen University.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 1 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: status not confirmed, as of the sponsor's last update on 8 Dec 2015. Status can change between updates, so confirm with the study contact before making plans.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
Results are not available in the source record.
How can a doctor refer a patient or contact the research team?
Contact Qinchang Chen, Doctor (18819430530, 337809622@qq.com), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
The survival rate (time frame: 3 years). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 8 Dec 2015.